CHI’s Second Annual Bispecific Case Studies & Clinical Relevance conference will bring together clinicians, regulators, and industry experts in the field to discuss and exchange ideas on promising bispecific candidates. We will showcase all crucial topics from understanding the biology behind different bispecific constructs to mitigating challenges in advancing novel platforms to the clinic. A companion diagnostic aspect for bispecific platforms will be examined for meaningful therapeutic selection based on patient identification, stratification, and the early assessment of treatment efficacies. An extension of bispecific applications in other diseases besides oncology will also be discussed.

Preliminary Agenda

CLINICAL UPDATES FOR BISPECIFICS AND COMBINATIONS

Introduction and Overview of Bispecific Antibodies in The Clinic

Rakesh Dixit, Vice President, Global Head, MedImmune, Inc.

ABL001 (NOV1501): A Novel Bispecific Antibody Targeting VEGF & DLL4 for the Treatment of Solid Tumors

Sang Hoon Lee, PhD, CEO, ABL Bio

Lessons Learned From the Bis4Ab platform: From a Bispecific Engineering Concept to Clinical Investigation.

Nazzareno Dimasi, PhD Associate Director R&D MedImmune

Leveraging Host Anti-Tumor Immunity through Bi-Specific DART® Molecule

Paul A. Moore, PhD, Vice President, Cell Biology & Immunology, MacroGenics, Inc.

M7824 (MSB0011359C), A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Advanced Solid Tumors

Julius Strauss, MD, Assistant Research Physician, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, NCI, NIH

UNDERSTANDING THE BIOLOGY FOR ENHANCED SAFETY AND EFFICACY

Bioassay Development for Bispecific Antibody from an FDA Standpoint

Wen Jin Wu, MD, PhD, Senior Investigator, Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA CDER

Design Meets Biology – Engineering a PD-1/CTLA-4 Bispecific Antibody to Improve Both Safety and Efficacy

Yariv Mazor, PhD, Senior Scientist, Antibody Discovery & Protein Engineering, MedImmune

Tumor Microenvironment and Its Impact on Bispecifics

Tariq Ghayur, PhD, Distinguished Research Fellow, Immunology Discovery, AbbVie

IMMUNOGENICITY AND CLINICAL PHARMACOLOGY CONSIDERATIONS

Clinical Pharmacology Considerations of Bispecific Antibodies

Ping Ji, PhD, Pharmacologist, OCP, FDA

Immunogenicity Assessment of Bispecific Antibody Therapeutics in Clinical Studies

Kate Peng, PhD, Group Leader/Senior Scientist, BioAnalytical Sciences, Genentech




For more details on the conference, please contact:
Emily Le

Conference Producer

[Cambridge Healthtech Institute]

Phone: 781-247-1812
Email: ele@healthtech.com

 

For partnering and sponsorship information, please contact:

Companies A-K

Jason Gerardi

Senior Manager, Business Development

[Cambridge Healthtech Institute]

Phone: 781-972-5452
Email: jgerardi@healthtech.com

 

Companies L-Z

Carol Dinerstein

Senior Manager, Business Development

[Cambridge Healthtech Institute]

Phone: 781-972-5471
Email: dinerstein@healthtech.com

 

 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag

Register